P1345: EFFECT OF DECITABINE ON MACROPHAGE PHENOTYPE AND FUNCTION IN VITRO IN THE CONTEXT OF AML

P1345: EFFECT OF DECITABINE ON MACROPHAGE PHENOTYPE AND FUNCTION IN VITRO IN THE CONTEXT OF AML

Bibliographic Details
Main Authors:	Jacobien Hilberink, Isabel Weinhäuser, Diego Pereira-Martins, Jan Jacob Schuringa, Gerwin Huls
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000972268.56144.71

Similar Items

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
by: Jacobien R. Hilberink, et al.
Published: (2023-06-01)

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
by: Hongjiao Li, et al.
Published: (2023-09-01)

High <i>ME1</i> Expression Is a Molecular Predictor of Post-Transplant Survival of Patients with Acute Myeloid Leukemia
by: César Alexander Ortiz Rojas, et al.
Published: (2022-12-01)

ELMO1 is upregulated in AML CD34+ stem/progenitor cells, mediates chemotaxis and predicts poor prognosis in normal karyotype AML.
by: Marta E Capala, et al.
Published: (2014-01-01)

Decitabine Promotes Modulation in Phenotype and Function of Monocytes and Macrophages That Drive Immune Response Regulation
by: Fabiana Albani Zambuzi, et al.
Published: (2021-04-01)

Synchronous AML and pancreatic neuroendocrine neoplasm, both successfully treated with somatostatin analogs and decitabine
by: Syed Ehsanullah, et al.
Published: (2023-01-01)

A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML
by: Lia Gore, et al.
Published: (2017-10-01)

S127: DELTATP73 IMPOSES TP53 MUTANT-LIKE PHENOTYPES INCLUDING DRUG RESISTANCE AND POOR PROGNOSIS ON TP53-WILD TYPE ACUTE MYELOID LEUKEMIA.
by: Diego A Pereira-Martins, et al.
Published: (2023-08-01)

A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML
by: Brian A. Jonas, et al.
Published: (2023-01-01)

S252: M2-POLARIZED MACROPHAGES CONTROL LEUKEMIC STEM CELL FATE BY PROMOTING METABOLIC REPROGRAMMING
by: I. Weinhäuser, et al.
Published: (2022-06-01)

VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses
by: Yusheng Lin, et al.
Published: (2024-03-01)

The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation
by: Ruth Meier, et al.
Published: (2022-08-01)

P471: ERYTHROID/MEGAKARYOCYTIC DIFFERENTIATION BIAS IN BONE MARROW OF AML/MDS PATIENTS AFTER DECITABINE TREATMENT
by: F. Tiso, et al.
Published: (2022-06-01)

Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
by: Nora Rebeka Javorniczky, et al.
Published: (2023-11-01)

P466: THE INTRINSICALLY DISORDERED TRANSCRIPTIONAL REGULATOR MN1 DEPENDS ON THE CHAPERONE DNAJB6B FOR ITS FULL TRANSFORMING POTENTIAL
by: Diego A Pereira-Martins, et al.
Published: (2023-08-01)

Inhibition of the succinyl dehydrogenase complex in acute myeloid leukemia leads to a lactate-fuelled respiratory metabolic vulnerability
by: Ayşegül Erdem, et al.
Published: (2022-04-01)

The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy
by: Keli Lima, et al.
Published: (2022-11-01)

PB1849: EARLY SALVAGE THERAPY WITH VENETOCLAX AND 10-DAY DECITABINE IS FEASIBLE AND SAFE IN REFRACTORY AML: RESULTS FROM 11 PATIENTS WITH EARLY INDUCTION FAILURE
by: Carla Borst, et al.
Published: (2023-08-01)

Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study
by: Jing Liu, et al.
Published: (2022-01-01)

Archbishopric of Serres under the auspices of the Serbian state from 1345 to 1371
by: Antić Dejan D.
Published: (2015-01-01)

Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation
by: Jinye Zhu, et al.
Published: (2023-10-01)

Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia
by: Briot T, et al.
Published: (2017-11-01)

Los escribanos públicos de Palma del Río (Córdoba), 1345-1400
by: Pilar Ostos Salcedo
Published: (1990-12-01)

Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
by: Taichun Qin, et al.
Published: (2011-01-01)

Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
by: Daehun Kwag, et al.
Published: (2022-12-01)

The Ystoria Ethyopie in the Cronica Universalis of Galvaneus de la Flamma (d. c.1345)
by: Alessandro Bausi, et al.
Published: (2020-03-01)

Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons
by: Tremblay G, et al.
Published: (2019-09-01)

Signal regulatory protein beta 2 is a novel positive regulator of innate anticancer immunity
by: Nienke Visser, et al.
Published: (2023-12-01)

Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies
by: Vanessa Kohl, et al.
Published: (2019-10-01)

S247: ADDING RUXOLITINIB AND DECITABINE TO BU/CY CONDITIONING REGIMENS TO PROPHYLAXIS POST-TRANSPLANT RELAPSE IN HIGH-RISK AML IS SAFE AND EFFECTIVE: A PROSPECTIVE, PHASE II STUDY
by: Yujun Wei, et al.
Published: (2023-08-01)

Clemente VI, Venezia e il ridimensionamento di un’impresa trecentesca (1343-1345)
by: Filippo Vaccaro
Published: (2023-12-01)

El forment a la Barcelona baixmedieval: preus, mesures i fiscalitat (1283-1345)
by: Pere Ortí i Gost
Published: (1992-12-01)

PB1772: HIGH SLIT2 LEVELS ARE ASSOCIATED WITH GMP LIKE AML AND TREATMENT WITH RECOMBINANT SLIT2 INHIBITS LEUKEMOGENESIS
by: Luise Araujo de Albuquerque Simoes, et al.
Published: (2023-08-01)

S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY (“3 + 7”) FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG
by: M. Lübbert, et al.
Published: (2022-06-01)

P440: THE COMBINATION VENETOCLAX PLUS MCL1 OVERCOMES DRUG RESISTANCE IN ACUTE PROMYELOCYTIC LEUKEMIA
by: D. A. Pereira-Martins, et al.
Published: (2022-06-01)

A luminescence-based method to assess antigen presentation and antigen-specific T cell responses for in vitro screening of immunomodulatory checkpoints and therapeutics
by: Jimena Álvarez Freile, et al.
Published: (2023-07-01)

TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
by: Friedrich Haag, et al.
Published: (2022-12-01)

The dominant discourse over women’s education in high school text books (1320-1345 S.H)
by: fatemeh samiee, et al.
Published: (2023-07-01)

Anne-Maria van Egmond, Materiële representatie opgetekend aan het Haagse hof 1345-1425
by: Gerrit Verhoeven
Published: (2021-11-01)

Selinexor in Combination with Decitabine Attenuates Ovarian Cancer in Mice
by: Patrick J. Stiff, et al.
Published: (2023-09-01)